The moral corporation--Merck experiences
Merck and the pharmaceutical industry are headline news today. Controversies over public safety, prices, and the ability of the industry to develop the new drugs and vaccines that society needs have been covered worldwide. Roy Vagelos, who was head of research and then CEO at Merck from the mid-1970...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Cambridge
Cambridge University Press
2006
|
| Schlagworte: | |
| Online-Zugang: | BSB01 UBG01 URL des Erstveröffentlichers |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043925234 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 161202s2006 |||| o||u| ||||||eng d | ||
| 020 | |a 9780511616860 |c Online |9 978-0-511-61686-0 | ||
| 024 | 7 | |a 10.1017/CBO9780511616860 |2 doi | |
| 035 | |a (ZDB-20-CBO)CR9780511616860 | ||
| 035 | |a (OCoLC)967484492 | ||
| 035 | |a (DE-599)BVBBV043925234 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 |a DE-473 | ||
| 082 | 0 | |a 338.7/616151092 |2 22 | |
| 100 | 1 | |a Vagelos, P. Roy |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a The moral corporation--Merck experiences |c P. Roy Vagelos, Louis Galambos |
| 264 | 1 | |a Cambridge |b Cambridge University Press |c 2006 | |
| 300 | |a 1 online resource (ix, 185 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Title from publisher's bibliographic system (viewed on 05 Oct 2015) | ||
| 505 | 8 | |a The puzzle -- The professional path -- Turn around -- New drugs and public safety -- Corporate grooming -- Winning in global competition -- Prices and the public interest -- Moral leadership -- Afterwards | |
| 520 | |a Merck and the pharmaceutical industry are headline news today. Controversies over public safety, prices, and the ability of the industry to develop the new drugs and vaccines that society needs have been covered worldwide. Roy Vagelos, who was head of research and then CEO at Merck from the mid-1970s through the early 1990s, addresses these issues here. Success with targeted research started Merck on a path that would lead to a series of block-buster therapies that carried the firm to the top of the global industry in the 1990s and Vagelos into the top position at the company. Trained as a physician and scientist, he had to learn how to run a successful business while holding to the highest principles of ethical behavior. He was not always successful. He and his co-author explain where and why he failed to achieve his goals and carefully analyze where he succeeded | ||
| 600 | 1 | 4 | |a Vagelos, P. Roy |
| 600 | 1 | 7 | |a Vagelos, Pindaros Roy |d 1929- |0 (DE-588)129048933 |2 gnd |9 rswk-swf |
| 610 | 2 | 4 | |a Merck & Co / Management |
| 610 | 2 | 7 | |a Merck & Co. |0 (DE-588)5284383-X |2 gnd |9 rswk-swf |
| 648 | 7 | |a Geschichte 1975.1995 |2 gnd |9 rswk-swf | |
| 648 | 7 | |a Geschichte 1975-1995 |2 gnd |9 rswk-swf | |
| 650 | 4 | |a Ethik | |
| 650 | 4 | |a Pharmaceutical industry / Moral and ethical aspects / United States | |
| 650 | 4 | |a Business ethics | |
| 650 | 4 | |a Social responsibility of business | |
| 650 | 0 | 7 | |a Soziale Verantwortung |0 (DE-588)4055737-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelversorgung |0 (DE-588)4140783-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelsicherheit |0 (DE-588)4143182-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Wirtschaftsethik |0 (DE-588)4066439-9 |2 gnd |9 rswk-swf |
| 651 | 4 | |a USA | |
| 651 | 7 | |a USA |0 (DE-588)4078704-7 |2 gnd |9 rswk-swf | |
| 655 | 7 | |0 (DE-588)4003939-0 |a Autobiografie |2 gnd-content | |
| 655 | 7 | |8 1\p |0 (DE-588)1071854844 |a Fiktionale Darstellung |2 gnd-content | |
| 689 | 0 | 0 | |a Merck & Co. |0 (DE-588)5284383-X |D b |
| 689 | 0 | 1 | |a Arzneimittelsicherheit |0 (DE-588)4143182-0 |D s |
| 689 | 0 | 2 | |a Soziale Verantwortung |0 (DE-588)4055737-6 |D s |
| 689 | 0 | 3 | |a Geschichte 1975.1995 |A z |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Merck & Co. |0 (DE-588)5284383-X |D b |
| 689 | 1 | 1 | |a Arzneimittelversorgung |0 (DE-588)4140783-0 |D s |
| 689 | 1 | 2 | |a Soziale Verantwortung |0 (DE-588)4055737-6 |D s |
| 689 | 1 | 3 | |a Geschichte 1975-1995 |A z |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a USA |0 (DE-588)4078704-7 |D g |
| 689 | 2 | 1 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |D s |
| 689 | 2 | 2 | |a Wirtschaftsethik |0 (DE-588)4066439-9 |D s |
| 689 | 2 | |5 DE-604 | |
| 689 | 3 | 0 | |a Vagelos, Pindaros Roy |d 1929- |0 (DE-588)129048933 |D p |
| 689 | 3 | |5 DE-604 | |
| 700 | 1 | |a Galambos, Louis |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druckausgabe |z 978-0-521-68383-8 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druckausgabe |z 978-0-521-86455-8 |
| 856 | 4 | 0 | |u https://doi.org/10.1017/CBO9780511616860 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-20-CBO | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029334313 | ||
| 883 | 1 | |8 1\p |a sdnb2form |d 20230710 |q DE-101 |h ttps://www.bib-bvb.de/rovenienzkennzeichnungen/Uebersicht.html#sdnb2form | |
| 966 | e | |u https://doi.org/10.1017/CBO9780511616860 |l BSB01 |p ZDB-20-CBO |q BSB_PDA_CBO |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1017/CBO9780511616860 |l UBG01 |p ZDB-20-CBO |q UBG_PDA_CBO |x Verlag |3 Volltext | |
Datensatz im Suchindex
| DE-BY-UBG_katkey | 196330436 |
|---|---|
| DE-BY-UBG_local_url | Verlag https://doi.org/10.1017/CBO9780511616860 |
| _version_ | 1811360855721246720 |
| any_adam_object | |
| author | Vagelos, P. Roy |
| author_facet | Vagelos, P. Roy |
| author_role | aut |
| author_sort | Vagelos, P. Roy |
| author_variant | p r v pr prv |
| building | Verbundindex |
| bvnumber | BV043925234 |
| collection | ZDB-20-CBO |
| contents | The puzzle -- The professional path -- Turn around -- New drugs and public safety -- Corporate grooming -- Winning in global competition -- Prices and the public interest -- Moral leadership -- Afterwards |
| ctrlnum | (ZDB-20-CBO)CR9780511616860 (OCoLC)967484492 (DE-599)BVBBV043925234 |
| dewey-full | 338.7/616151092 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.7/616151092 |
| dewey-search | 338.7/616151092 |
| dewey-sort | 3338.7 9616151092 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| doi_str_mv | 10.1017/CBO9780511616860 |
| era | Geschichte 1975.1995 gnd Geschichte 1975-1995 gnd |
| era_facet | Geschichte 1975.1995 Geschichte 1975-1995 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04583nmm a2200841zc 4500</leader><controlfield tag="001">BV043925234</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">161202s2006 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780511616860</subfield><subfield code="c">Online</subfield><subfield code="9">978-0-511-61686-0</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1017/CBO9780511616860</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-20-CBO)CR9780511616860</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)967484492</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043925234</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-473</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">338.7/616151092</subfield><subfield code="2">22</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Vagelos, P. Roy</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The moral corporation--Merck experiences</subfield><subfield code="c">P. Roy Vagelos, Louis Galambos</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge</subfield><subfield code="b">Cambridge University Press</subfield><subfield code="c">2006</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (ix, 185 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Title from publisher's bibliographic system (viewed on 05 Oct 2015)</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">The puzzle -- The professional path -- Turn around -- New drugs and public safety -- Corporate grooming -- Winning in global competition -- Prices and the public interest -- Moral leadership -- Afterwards</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Merck and the pharmaceutical industry are headline news today. Controversies over public safety, prices, and the ability of the industry to develop the new drugs and vaccines that society needs have been covered worldwide. Roy Vagelos, who was head of research and then CEO at Merck from the mid-1970s through the early 1990s, addresses these issues here. Success with targeted research started Merck on a path that would lead to a series of block-buster therapies that carried the firm to the top of the global industry in the 1990s and Vagelos into the top position at the company. Trained as a physician and scientist, he had to learn how to run a successful business while holding to the highest principles of ethical behavior. He was not always successful. He and his co-author explain where and why he failed to achieve his goals and carefully analyze where he succeeded</subfield></datafield><datafield tag="600" ind1="1" ind2="4"><subfield code="a">Vagelos, P. Roy</subfield></datafield><datafield tag="600" ind1="1" ind2="7"><subfield code="a">Vagelos, Pindaros Roy</subfield><subfield code="d">1929-</subfield><subfield code="0">(DE-588)129048933</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="610" ind1="2" ind2="4"><subfield code="a">Merck & Co / Management</subfield></datafield><datafield tag="610" ind1="2" ind2="7"><subfield code="a">Merck & Co.</subfield><subfield code="0">(DE-588)5284383-X</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="648" ind1=" " ind2="7"><subfield code="a">Geschichte 1975.1995</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="648" ind1=" " ind2="7"><subfield code="a">Geschichte 1975-1995</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ethik</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry / Moral and ethical aspects / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Business ethics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social responsibility of business</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Soziale Verantwortung</subfield><subfield code="0">(DE-588)4055737-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelversorgung</subfield><subfield code="0">(DE-588)4140783-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelsicherheit</subfield><subfield code="0">(DE-588)4143182-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Wirtschaftsethik</subfield><subfield code="0">(DE-588)4066439-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4003939-0</subfield><subfield code="a">Autobiografie</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="8">1\p</subfield><subfield code="0">(DE-588)1071854844</subfield><subfield code="a">Fiktionale Darstellung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Merck & Co.</subfield><subfield code="0">(DE-588)5284383-X</subfield><subfield code="D">b</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelsicherheit</subfield><subfield code="0">(DE-588)4143182-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Soziale Verantwortung</subfield><subfield code="0">(DE-588)4055737-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Geschichte 1975.1995</subfield><subfield code="A">z</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Merck & Co.</subfield><subfield code="0">(DE-588)5284383-X</subfield><subfield code="D">b</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Arzneimittelversorgung</subfield><subfield code="0">(DE-588)4140783-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Soziale Verantwortung</subfield><subfield code="0">(DE-588)4055737-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="3"><subfield code="a">Geschichte 1975-1995</subfield><subfield code="A">z</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="2"><subfield code="a">Wirtschaftsethik</subfield><subfield code="0">(DE-588)4066439-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="3" ind2="0"><subfield code="a">Vagelos, Pindaros Roy</subfield><subfield code="d">1929-</subfield><subfield code="0">(DE-588)129048933</subfield><subfield code="D">p</subfield></datafield><datafield tag="689" ind1="3" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Galambos, Louis</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druckausgabe</subfield><subfield code="z">978-0-521-68383-8</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druckausgabe</subfield><subfield code="z">978-0-521-86455-8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1017/CBO9780511616860</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-20-CBO</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029334313</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">sdnb2form</subfield><subfield code="d">20230710</subfield><subfield code="q">DE-101</subfield><subfield code="h">ttps://www.bib-bvb.de/rovenienzkennzeichnungen/Uebersicht.html#sdnb2form</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1017/CBO9780511616860</subfield><subfield code="l">BSB01</subfield><subfield code="p">ZDB-20-CBO</subfield><subfield code="q">BSB_PDA_CBO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1017/CBO9780511616860</subfield><subfield code="l">UBG01</subfield><subfield code="p">ZDB-20-CBO</subfield><subfield code="q">UBG_PDA_CBO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4003939-0 Autobiografie gnd-content 1\p (DE-588)1071854844 Fiktionale Darstellung gnd-content |
| genre_facet | Autobiografie Fiktionale Darstellung |
| geographic | USA USA (DE-588)4078704-7 gnd |
| geographic_facet | USA |
| id | DE-604.BV043925234 |
| illustrated | Not Illustrated |
| index_date | 2024-09-20T13:29:36Z |
| indexdate | 2024-09-27T16:41:23Z |
| institution | BVB |
| isbn | 9780511616860 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029334313 |
| oclc_num | 967484492 |
| open_access_boolean | |
| owner | DE-12 DE-473 DE-BY-UBG |
| owner_facet | DE-12 DE-473 DE-BY-UBG |
| physical | 1 online resource (ix, 185 pages) |
| psigel | ZDB-20-CBO ZDB-20-CBO BSB_PDA_CBO ZDB-20-CBO UBG_PDA_CBO |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | Cambridge University Press |
| record_format | marc |
| spellingShingle | Vagelos, P. Roy The moral corporation--Merck experiences The puzzle -- The professional path -- Turn around -- New drugs and public safety -- Corporate grooming -- Winning in global competition -- Prices and the public interest -- Moral leadership -- Afterwards Vagelos, P. Roy Vagelos, Pindaros Roy 1929- (DE-588)129048933 gnd Merck & Co / Management Merck & Co. (DE-588)5284383-X gnd Ethik Pharmaceutical industry / Moral and ethical aspects / United States Business ethics Social responsibility of business Soziale Verantwortung (DE-588)4055737-6 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd Arzneimittelversorgung (DE-588)4140783-0 gnd Arzneimittelsicherheit (DE-588)4143182-0 gnd Wirtschaftsethik (DE-588)4066439-9 gnd |
| subject_GND | (DE-588)129048933 (DE-588)5284383-X (DE-588)4055737-6 (DE-588)4045696-1 (DE-588)4140783-0 (DE-588)4143182-0 (DE-588)4066439-9 (DE-588)4078704-7 (DE-588)4003939-0 (DE-588)1071854844 |
| title | The moral corporation--Merck experiences |
| title_auth | The moral corporation--Merck experiences |
| title_exact_search | The moral corporation--Merck experiences |
| title_full | The moral corporation--Merck experiences P. Roy Vagelos, Louis Galambos |
| title_fullStr | The moral corporation--Merck experiences P. Roy Vagelos, Louis Galambos |
| title_full_unstemmed | The moral corporation--Merck experiences P. Roy Vagelos, Louis Galambos |
| title_short | The moral corporation--Merck experiences |
| title_sort | the moral corporation merck experiences |
| topic | Vagelos, P. Roy Vagelos, Pindaros Roy 1929- (DE-588)129048933 gnd Merck & Co / Management Merck & Co. (DE-588)5284383-X gnd Ethik Pharmaceutical industry / Moral and ethical aspects / United States Business ethics Social responsibility of business Soziale Verantwortung (DE-588)4055737-6 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd Arzneimittelversorgung (DE-588)4140783-0 gnd Arzneimittelsicherheit (DE-588)4143182-0 gnd Wirtschaftsethik (DE-588)4066439-9 gnd |
| topic_facet | Vagelos, P. Roy Vagelos, Pindaros Roy 1929- Merck & Co / Management Merck & Co. Ethik Pharmaceutical industry / Moral and ethical aspects / United States Business ethics Social responsibility of business Soziale Verantwortung Pharmazeutische Industrie Arzneimittelversorgung Arzneimittelsicherheit Wirtschaftsethik USA Autobiografie Fiktionale Darstellung |
| url | https://doi.org/10.1017/CBO9780511616860 |
| work_keys_str_mv | AT vagelosproy themoralcorporationmerckexperiences AT galamboslouis themoralcorporationmerckexperiences |